Published in final edited form as:

Org Lett. 2009 August 6; 11(15): 3186–3189. doi:10.1021/ol900971r.

New Sources of Chemical Diversity Inspired by Biosynthesis: Rational Design of a Potent Epothilone Analogue

Jeffrey D. Frein¹, Richard E. Taylor^{*,1}, and Dan L. Sackett²

¹Department of Chemistry and Biochemistry and the Walther Cancer Research Center University of Notre Dame, 251 Nieuwland Science Hall. Notre Dame, IN 46556-5670

²Laboratory of Integrated and Medical Biophysics, National Institute of Child Health and Human Development, National Institutes of Health, 9 Memorial Drive, Bethesda, MD 20892-0924

Abstract

R = H epothilone C **1a**
R = Me epothilone D **1b**

S-14-methoxy-epothilone D **2**

A concise total synthesis of *S*-14-methoxy-epothilone D has been accomplished. *S*-14-Methoxy-epothilone D represents a conceptually novel example of polyketide analogue design based on an alternative biogenetic pattern of extender units. The significant biological activity observed for this compound provides a foundation to support studies designed to prepare derivatives of this type through fermentation of genetically engineered organisms expressing the epothilone PKS gene cluster.

Polyketide natural products are typically produced by microorganisms to create an environmental advantage for the producing organism through antibiotic and antifungal activity. Their structures evolve during the ancestral history of the producing organism through modification in their PKS gene clusters and the development or sequestration of genes encoding post-PKS processing enzymes.¹ The polyketide backbone is generated through the sequential incorporation of two-carbon extender units derived most commonly from malonyl-CoA or methylmalonyl-CoA. Advances in the genetic engineering of the gene clusters responsible for the production of biological active polyketides represents a valuable new source of chemical

*taylor.61@nd.edu.

Supporting Information Available: Full experimental and characterization data for all new compounds. This material is available free of charge via the Internet at <http://pubs.acs.org>.

diversity essential to identification of the next generation of chemotherapeutic agents.² Unfortunately, the biological implications of even minor structural modifications are typically difficult to predict. Our unique approach to this classic structure-activity relationship (SAR) problem was based on the initial appreciation that the main role for the functionality that adorns a polyketide is to control the overall conformation. Through extensive computer-based conformational analysis coupled with solution NMR studies on the naturally-occurring epothilones as well as designed analogues, we were able to develop a conformational activity relationship profile which was used to propose a binding conformation for the class.^{3,4,5,6} With this information in hand it is possible to design biologically active analogues of the epothilones, such as epothilones C and D, Figure 1, which may be accessible through genetic engineering.

Herein we report the total synthesis and biological evaluation of *S*-14-methoxy-epothilone **D** **2**, a novel epothilone analogue. The stereochemistry of the C14-substitution was chosen to provide further support for the proposed binding conformation in the C11-C15 region.⁷ Moreover, the incorporation of a methoxy group at this position represents a target potentially available through modification to the acyltransferase domain of module 3 in the epothilone PKS gene cluster⁸ and the incorporation of an extender unit derived from methoxymalonyl CoA.⁹

The significant efforts required to develop a fermentation based route could be justified if the biological activity of the target were significant. Thus, a synthetic strategy for the production of *S*-14-methoxy-epothilone **D** was developed based upon modifications to our previously reported route to epothilones **B** and **D**.¹⁰ This route relied on a sequential Nozaki-Hiyama-Kishi (NHK)¹¹ coupling thionyl chloride induced allylic rearrangement¹² to stereoselectively generate the C12-C13 trisubstituted olefin.

The starting thiazole aldehyde fragment **3** was prepared by previously described methods and detailed in Scheme 1.¹³ The introduction of the C14 methoxy substituent was accomplished via an asymmetric Brown allylation¹⁴ with lithiated allyl methyl ether in the presence of BF₃•OEt₂ to afford the alcohol **4** as a single diastereomer in >95% *ee*¹⁵ and 88% yield, Scheme 1. The undersired *syn*-stereochemistry was easily converted to the *anti*-diastereomer via a two step sequence. First, oxidation of the alcohol was achieved with Dess-Martin periodinane¹⁶ followed by a highly diastereoselective Luche reduction of the α , β -unsaturated ketone.¹⁷ This reduction yielded the optically pure *anti*-diastereomer **5** as a 93:7 mixture of diastereomers in 96% yield. The free hydroxyl group was protected with *t*-butoxydiphenylsilyl chloride (TBODPSCI) and subsequent oxidative cleavage of the terminal olefin under standard conditions afforded the desired aldehyde fragment **6**.

As shown in Scheme 2, fragment coupling of aldehyde **6** with known vinyl iodide fragment **7**, prepared according to a previously reported route,¹⁰ was achieved via a NHK coupling reaction. This key step afforded the desired allylic alcohol as a 3:1 mixture of unassigned and inconsequential diastereomers in 78% yield. Exposure of this mixture to thionyl chloride in ether-pentane provided the desired primary chloride **8** in 80% yield as a single olefin isomer.

Removal of the chiral auxiliary and cleavage of the primary chloride was achieved in a single synthetic operation utilizing LiEt₃BH, which was subsequently oxidized with Dess-Martin periodinane to afford the aldehyde **9**. The synthesis of the C1-C6 fragment, Scheme 3, commenced with the readily available silyl ketene acetal **10**¹⁸ and ketoaldehyde **11**.¹⁹ Treatment with Kiyooka's chiral boron reagent²⁰ (100 mol%) provided the TMS-protected aldol adduct **12** in 69% yield and >95% *ee*. The TMS group was readily removed with TFA and the resultant secondary alcohol was protected with TBSOTf in the presence of 2,6-lutidine to afford the C1-C6 fragment **13** in 91% yield.

Aldol coupling between ketone fragment **13** and aldehyde **9** was accomplished by the previously reported, highly diastereoselective Ti-mediated coupling conditions.²¹ In our system, when **13** was treated with TiCl₄ and *i*-Pr₂NEt and then subsequently **9**, the *syn,anti*-aldol product **14** was obtained in 80% yield and as a single diastereomer. The resultant secondary alcohol was protected as the TBS ether with TBSOTf and 2,6-lutidine in 95% yield. Hydrolysis of the phenyl ester under standard conditions (LiOH in THF/H₂O) provided a small amount of the desired acid, as well as a large amount of C3 elimination product. After screening various conditions, this problem was overcome by the use of milder hydrolysis conditions (NaHCO₃ and H₂O₂ in THF), which afforded the desired acid in 85% yield without any formation of a C3-elimination product. Subsequent selective removal of the C15 TBODPS ether was accomplished by careful treatment with TBAF at 0 °C to afford the *seco*-acid **15** in 75% yield. Classic Yamaguchi macrolactonization conditions²² using trichlorobenzoyl chloride (TCBCl) provided the 16-membered lactone in good yield when heated to 40 °C. Finally, global deprotection was carried out using HF•py to afford *S*-14-methoxyepothilone D **2** in 88% yield.

The biological activity of *S*-14-methoxyepothilone D **2** was evaluated against a two human tumor cell lines (Table 1) in direct comparison to natural epothilone B, ixabepilone, and paclitaxel. The presence of a C12,C13 epoxide as in epothilone B is known to enhance activity by an order of magnitude. Ixabepilone is Bristol-Myers Squibb's semi-synthetic analogue of epothilone B recently approved by the FDA for advanced breast cancer therapy.²³ *S*-14-Methoxyepothilone D retains significant cytotoxic activity on par with both naturally occurring as well as synthetically derived analogues of the epothilones.

S-14-Methoxyepothilone D represents a conceptually novel example of polyketide analogue design based on an alternative biogenetic pattern of extender units. The significant biological activity observed for this compound provides a foundation to support studies designed to prepare derivatives of this type through fermentation of genetic engineered organisms expressing the modified forms of the epothilone PKS gene cluster and/or precursor-directed biosynthesis. Results along these lines will be reported in due course.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgment

Dr. Bandaru Sreenivasulu (Notre Dame) is acknowledged for preliminary studies. Support provided by the National Institutes of General Medical Sciences (GM077683) is gratefully acknowledged. JDF thanks the Walther Cancer Research Center (Notre Dame) for fellowship support. This work was supported in part by intramural funds of the Eunice Kennedy Shriver National Institute for Child Health and Human Development.

References

1. Ridley CP, Lee HY, Khosla C. Proc. Nat. Acad. Sci 2008;105:4595–4600. [PubMed: 18250311]
2. Kealey JT. Front. Biosci 2003;8:C1–C13. [PubMed: 12456305]
3. Taylor RE, Chen Y, Galvin GM, Pabba PK. Org. Biomol. Chem 2004;2:127–132. [PubMed: 14737671]
4. Carlomagno T, Blommers MJJ, Meiler J, Jahnke W, Schupp T, Peterson F, Schinzer D, Altmann K-H, Griesinger C. Angew. Chem., Int. Ed 2003;42:2511–2515.
5. An alternative binding conformation has been proposed based on electron crystallography: Nettles JH, Li H, Cornett B, Krahn JM, Snyder JP, Downing KH. Science 2004;305:866–869.869 [PubMed: 15297674]

6. A critical review of published efforts towards identification of the binding conformation of the epothilones has been published: Heinz DW, Schubert W-D, Höfle G. *Angew. Chem., Int. Ed* 2005;44:1298–1301.1301
7. Taylor RE, Chen Y, Beatty A, Myles DC, Zhou Y. *J. Am. Chem. Soc* 2003;125:26–27. [PubMed: 12515494]
8. Tang L, Shah S, Chung L, Carney J, Katz L, Khosla C, Julien B. *Science* 2000;199:640–642. [PubMed: 10649995]
9. Chan YA, Boyne MT II, Podevels AM, Klimowicz AK, Handelsman J, Kelleher NL, Thomas MG. *Proc. Nat. Acad. Sci* 2006;103:14349–14354. [PubMed: 16983083]
10. Taylor RE, Chen Y. *Org. Lett* 2001;3:2221–2224. [PubMed: 11440584]
- 11 (a). Takai K, Tagashira M, Kuroda T, Oshima K, Utimoto K, Nozaki H. *J. Am. Chem. Soc* 1986;108:6048–6050. (b) Jin H, Uenishi J-I, Christ WJ, Kishi Y. *J. Am. Chem. Soc* 1986;108:5644–5646.
12. Caserio FF, Dennis GE, DeWolfe RH, Young WG. *J. Am. Chem. Soc* 1955;77:4182–4183.
13. Taylor RE, Haley JD. *Tetrahedron Lett* 1997;38:2061–2064.
- 14 a). Brown HC, Jadhav PK, Bhat KS. *J. Am. Chem. Soc* 1988;110:1535–1538. b) Hoffmann RW, Kemper B, Metternich R, Liebigs Lehmeier, T. *Ann. Chem* 1985:2246–2260.
15. Dale JA, Mosher HS. *J. Am. Chem. Soc* 1973;95:512–519.
- 16 a). Frigerio M, Santagostino M, Sputore S. *J. Org. Chem* 1999;64:4537–4538. b) Boeckman RK Jr. Shao P, Mullins JJ. *Org. Syn* 2004;77:141–146.
17. Luche J-L, Rodriguez-Hahn L, Crabbe P. *J. Chem. Soc., Chem. Comm* 1978:601–602.
18. Slougui N, Rousseau G. *Syn. Comm* 1987;17:1–11.
19. Inukai T, Yoshizawa R. *J. Org. Chem* 1967;32:404–407.
20. Kiyooka S-I, Kira H, Hena MA. *Tetrahedron Lett* 1996;37:2597–2600.
21. Koch G, Loiseleur O, Fuentes D, Jantsch A, Altmann K-H. *Org. Lett* 2002;4:3811–3814. [PubMed: 12599465]
22. Inanaga J, Hirata K, Saeki H, Katsuki T, Yamaguchi M. *Bull. Chem. Soc. Jpn* 1979;52:1989–1993.
23. <http://www.ixempra.com/http://www.ixempra.com/>

Figure 1.
The structures and biogenetic pattern for epothilones C and D; the structure of (*S*)-14-methoxy-epothilone D.

Scheme 1.
Installation of C14-Methoxy Substituent.

Scheme 2.
Sequential NHK Coupling/Thionyl Chloride Rearrangement for Trisubstituted Olefin
Generation.

Scheme 3.
Synthesis of C1-C6 Fragment.

Scheme 4.
Selective Aldol and Completion of Synthesis.

Table 1Cytotoxicity of Epothilone Analogs (IC₅₀ nM)

compound	MCF-7	H460
<i>S</i> -14-methoxyepothilone D 3	3.7	4.9
epothilone B	0.5	0.3
ixabepilone (Ixempra®)	2.1	2.3
paclitaxel (Taxol®)	4.7	1.5